Journal issues > Issue Special, March 2024 > Optimising the treatment for patients with recurrent prostate cancer

Optimising the treatment for patients with recurrent prostate cancer

During the 2024 BMUC meeting, an entire session was dedicated to the management of patients with recurrent prostate cancer. In this session, Dr. Alastair Lamb (University of Oxford, UK) highlighted the concept and assessment of biochemical relapse (BCR) post-prostatectomy, stressing the importance of risk stratification. Subsequently, Prof. Bertrand Tombal (Cliniques Universitaires Saint Luc, Belgium) discussed strategies to optimise the systemic therapy for patients at both low and high risk after which Prof. Piet Ost (Ghent University, Belgium) discussed the integration of metastasis-directed therapy with systemic approaches in patients with metachronous metastatic hormone-sensitive prostate cancer.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top